Annual EBITDA
-$202.70 M
+$446.29 M+68.77%
31 December 2023
Summary:
CRISPR Therapeutics AG annual earnings before interest, taxes, depreciation & amortization is currently -$202.70 million, with the most recent change of +$446.29 million (+68.77%) on 31 December 2023. During the last 3 years, it has risen by +$142.55 million (+41.29%). CRSP annual EBITDA is now -151.78% below its all-time high of $391.48 million, reached on 31 December 2021.CRSP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$105.39 M
+$41.02 M+28.02%
30 September 2024
Summary:
CRISPR Therapeutics AG quarterly earnings before interest, taxes, depreciation & amortization is currently -$105.39 million, with the most recent change of +$41.02 million (+28.02%) on 30 September 2024. Over the past year, it has increased by +$22.09 million (+17.33%). CRSP quarterly EBITDA is now -113.75% below its all-time high of $766.27 million, reached on 30 June 2021.CRSP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$313.08 M
+$22.09 M+6.59%
30 September 2024
Summary:
CRISPR Therapeutics AG TTM earnings before interest, taxes, depreciation & amortization is currently -$313.08 million, with the most recent change of +$22.09 million (+6.59%) on 30 September 2024. Over the past year, it has increased by +$89.80 million (+22.29%). CRSP TTM EBITDA is now -168.18% below its all-time high of $459.18 million, reached on 30 June 2021.CRSP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRSP EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +68.8% | +17.3% | +22.3% |
| 3 y3 years | +41.3% | +14.7% | -173.5% |
| 5 y5 years | -30.4% | -175.0% | -5882.7% |
CRSP EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -151.8% | +68.8% | -241.5% | +40.6% | -173.5% | +52.8% |
| 5 y | 5 years | -151.8% | +68.8% | -113.8% | +40.6% | -168.2% | +52.8% |
| alltime | all time | -151.8% | +68.8% | -113.8% | +40.6% | -168.2% | +52.8% |
CRISPR Therapeutics AG EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$105.39 M(-28.0%) | -$313.08 M(-6.6%) |
| June 2024 | - | -$146.41 M(+7.9%) | -$335.17 M(+20.1%) |
| Mar 2024 | - | -$135.75 M(-282.3%) | -$279.02 M(+37.7%) |
| Dec 2023 | -$202.70 M(-68.8%) | $74.48 M(-158.4%) | -$202.70 M(-49.7%) |
| Sept 2023 | - | -$127.49 M(+41.2%) | -$402.88 M(-11.0%) |
| June 2023 | - | -$90.26 M(+51.9%) | -$452.76 M(-15.9%) |
| Mar 2023 | - | -$59.44 M(-52.7%) | -$538.49 M(-17.0%) |
| Dec 2022 | -$648.99 M(-265.8%) | -$125.69 M(-29.1%) | -$648.99 M(-2.1%) |
| Sept 2022 | - | -$177.37 M(+0.8%) | -$662.73 M(+8.8%) |
| June 2022 | - | -$175.99 M(+3.6%) | -$608.89 M(-282.6%) |
| Mar 2022 | - | -$169.93 M(+21.9%) | $333.38 M(-14.8%) |
| Dec 2021 | $391.48 M(-213.4%) | -$139.44 M(+12.9%) | $391.48 M(-8.0%) |
| Sept 2021 | - | -$123.53 M(-116.1%) | $425.72 M(-7.3%) |
| June 2021 | - | $766.27 M(-785.2%) | $459.18 M(-219.1%) |
| Mar 2021 | - | -$111.83 M(+6.3%) | -$385.58 M(+11.7%) |
| Dec 2020 | -$345.25 M(-770.8%) | -$105.19 M(+16.8%) | -$345.25 M(+51.7%) |
| Sept 2020 | - | -$90.06 M(+14.7%) | -$227.64 M(-8034.5%) |
| June 2020 | - | -$78.50 M(+9.8%) | $2.87 M(-89.6%) |
| Mar 2020 | - | -$71.50 M(-675.9%) | $27.58 M(-46.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $51.47 M(-133.1%) | $12.41 M(-91.2%) | $51.47 M(-1083.5%) |
| Sept 2019 | - | $140.45 M(-361.1%) | -$5.23 M(-97.3%) |
| June 2019 | - | -$53.78 M(+13.0%) | -$194.23 M(+9.8%) |
| Mar 2019 | - | -$47.61 M(+7.5%) | -$176.86 M(+13.8%) |
| Dec 2018 | -$155.42 M(+152.2%) | -$44.28 M(-8.8%) | -$155.42 M(+42.1%) |
| Sept 2018 | - | -$48.55 M(+33.3%) | -$109.36 M(+30.8%) |
| June 2018 | - | -$36.42 M(+39.2%) | -$83.59 M(+23.3%) |
| Mar 2018 | - | -$26.17 M(-1571.9%) | -$67.77 M(+10.0%) |
| Dec 2017 | -$61.62 M(+348.4%) | $1.78 M(-107.8%) | -$61.62 M(+35.5%) |
| Sept 2017 | - | -$22.78 M(+10.6%) | -$45.49 M(+22.4%) |
| June 2017 | - | -$20.60 M(+2.9%) | -$37.16 M(+10.7%) |
| Mar 2017 | - | -$20.02 M(-211.8%) | -$33.56 M(+144.2%) |
| Dec 2016 | -$13.74 M(-46.3%) | $17.91 M(-223.9%) | -$13.74 M(-68.6%) |
| Sept 2016 | - | -$14.45 M(-15.0%) | -$43.71 M(+23.4%) |
| June 2016 | - | -$16.99 M(+7991.9%) | -$35.41 M(+92.2%) |
| Mar 2016 | - | -$210.00 K(-98.3%) | -$18.42 M(+1.2%) |
| Dec 2015 | -$25.59 M(+274.9%) | -$12.06 M(+96.0%) | -$18.21 M(+196.0%) |
| Sept 2015 | - | -$6.15 M | -$6.15 M |
| Dec 2014 | -$6.83 M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual EBITDA year-on-year change?
- What is CRISPR Therapeutics AG quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly EBITDA year-on-year change?
- What is CRISPR Therapeutics AG TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM EBITDA year-on-year change?
What is CRISPR Therapeutics AG annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CRSP is -$202.70 M
What is the all time high annual EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual earnings before interest, taxes, depreciation & amortization is $391.48 M
What is CRISPR Therapeutics AG annual EBITDA year-on-year change?
Over the past year, CRSP annual earnings before interest, taxes, depreciation & amortization has changed by +$446.29 M (+68.77%)
What is CRISPR Therapeutics AG quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CRSP is -$105.39 M
What is the all time high quarterly EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly earnings before interest, taxes, depreciation & amortization is $766.27 M
What is CRISPR Therapeutics AG quarterly EBITDA year-on-year change?
Over the past year, CRSP quarterly earnings before interest, taxes, depreciation & amortization has changed by +$22.09 M (+17.33%)
What is CRISPR Therapeutics AG TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CRSP is -$313.08 M
What is the all time high TTM EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM earnings before interest, taxes, depreciation & amortization is $459.18 M
What is CRISPR Therapeutics AG TTM EBITDA year-on-year change?
Over the past year, CRSP TTM earnings before interest, taxes, depreciation & amortization has changed by +$89.80 M (+22.29%)